EUVIMEDEUVIMED entdecken
Crossref

The effects of ulcerogenic drugs on the adverse events associated with nonvariceal upper gastrointestinal bleeding

D. Muhovic, K. Jankovic, N. Zdravkovic, B. Smolovic, S. Djuranovic

Endoscopy · 01.04.2024 · 56 (S 02 S 02) · S165

DOI: 10.1055/s-0044-1783053 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endoscopy, erschienen am 01.04.2024. Verfasst von D. Muhovic und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Although the incidence of nonvariceal upper gastrointestinal bleeding (NVUGIB) has been decreasing, the mortality rate is still significant and accounts up to 10% of cases. The increasing importance in the pathogenesis of the GI bleeding is the use of ulcerogenic medications. The study was aimed to asses the frequency of adverse events (AE) and their association with individual groups of ulcerogenic drugs (nonsteroidal anti-inflammatory drugs – NSAIDs, acetylsalicylic acid – ASA, oral anticoagulants – OAC, new oral anticoagulants – NOAC, antiplatelet drugs – APD, corticosteroids – CS, and selective serotonin reuptake inhibitors SSRI) in patients with NVUGIB.

Methods

This retrospective cross-sectional study included 301 patients who were admitted to our Center due to an episode of NVUGIB. The subjects were divided into the first group that consisted of those who used one or more ulcerogenic drugs (n=222, 73.8%), or the second group which included subjects who did not use any of the ulcerogenic drugs (n=79, 26.2%). We classified the AE into following: the need for transfusions of deplasmatized erythrocytes (DPE) and the need for endoscopic hemostasis (EH), while serious adverse events (SAE) were rebleeding (RB), surgical treatment, i.e. the need for surgical intervention (SI) and death within the first 30 days of discharge for further home treatment (D).

Results

In our cohort, a total of 370 AE were recorded, while the percentage of lethal outcome was 7.3%. The most represented ulcerogenic drugs were NSAIDs (49.2%), accompanied by ASA preparations (42.5%). Patients with NVUGIB that used ASA were significantly associated with rebleeding (p=0.024) and with fatal outcome in the first 30 days of treatment (p=0.003), as well as with the whole group of SAE (p=0.000). The use of NSAIDs was not significantly related with any individual SAE (rebleeding p=0.487, surgery p=0.669, mortality p=0.717), nor with the whole group of SAE (p=0.777). Patients who used CS also had no statistically significant association with individual serious adverse events (rebleeding p=0.095, surgery p=0.221, death p=0.282), nor with the entire SAE group (p=0.171). The lethal outcome in the first 30 days of treatment was significantly associated with the use of OAC and NOAC (p=0.024), as well as the use of antiplatelet drugs (p=0.003). The entire group of SAE, was also significantly related to the use of OAC/NOAC (p=0.001), as well as the use of APD (p=0.020).

Conclusions

Based on our results, the use of ASA significantly increases the possibility of rebleeding and death in the cohort. The use of APD was associated with fatal outcome and the whole group of SAE in patients with NVUGIB. We also concluded that the use of OAC/NOAC was significantly associated with death and the entire SAE group in patients with NVUGIB, while the use of NSAIDs or CS was not associated with a higher incidence of SAE in patients with NVUGIB. Publication History Article published online: 15 April 2024 © 2024. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Zitieren

APA

Muhovic, D., Jankovic, K., Zdravkovic, N., Smolovic, B., & Djuranovic, S. (2024). The effects of ulcerogenic drugs on the adverse events associated with nonvariceal upper gastrointestinal bleeding. Endoscopy, 56(S 02 S 02), S165. https://doi.org/10.1055/s-0044-1783053

Vancouver

Muhovic D, Jankovic K, Zdravkovic N, Smolovic B, Djuranovic S. The effects of ulcerogenic drugs on the adverse events associated with nonvariceal upper gastrointestinal bleeding. Endoscopy. 2024;56(S 02 S 02):S165. doi:10.1055/s-0044-1783053

BibTeX
@article{Muhovic2024,
  author = {Muhovic, D. and Jankovic, K. and Zdravkovic, N. and Smolovic, B. and Djuranovic, S.},
  title = {The effects of ulcerogenic drugs on the adverse events associated with nonvariceal upper gastrointestinal bleeding},
  journal = {Endoscopy},
  year = {2024},
  volume = {56},
  number = {S 02 S 02},
  pages = {S165},
  doi = {10.1055/s-0044-1783053}
}
Kostenlos starten →